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Hugo Fernandez,1,2 Lia Perez,1,2 Fred Locke,1,2 Melissa Alsina,1,2
Jose Leonel Ochoa,1,2 Janelle Perkins,1,2 Cheryl Tate,1 Jamie Shapiro,1 Michelle Conwell,1
Ryan Bookout,1 Claudio Anasetti1,2Severe acute graft-versus-host disease (aGVHD) remains a major source of morbidity and mortality follow-
ing mismatched unrelated donor hematopoietic cell transplantation (HCT). Through a retrospective analysis,
we investigated the efficacy of GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) 7.5 mg/kg (1 mg/
kg given on day23, then 3.25 mg/kg/day on days22 and21 before stem cell infusion) followed by standard
tacrolimus plus methotrexate in a consecutive series of 45 HLA partially matched unrelated donor HCTre-
cipients. The cumulative incidence of grade III-IV aGVHDwas 11% by 100 days (95% confidence interval [CI]
5%-25%). Moderate to severe chronic GVHD (per NIH consensus criteria) was 19% (95% CI 10%-36%) at 1
year, and 28% (95%CI 16%-48%) at 2 years.With a median follow-up time for surviving patients of 12 months
(range: 5-39 months), overall survival was 55% (95% CI 39%-71%) at 1 year, and 45% (95% CI 27%-63%) at 2
years. Nonrelapse mortality was 11% (95% CI 5%-25%) by 100 days post-HCT, 26% (95% CI 16%-44%) by 1
year, and 30% (95% CI 18%-50%) by 2 years. The cumulative incidence of primary disease relapse was 23%
(95% CI 13%-41%) at 1 year, and 33% (95% CI 20%-56%) by 2 years after HCT. Cytomegalovirus (CMV) in-
fection or reactivation varied according to recipient and donor CMV serostatus. Epstein-Barr Virus (EBV)
reactivation occurred in 54% (95% CI 40%-71%) of patients. Preemptive rituximab therapy was administered
for EBV reactivation, however, posttransplant lymphoproliferative disorder was diagnosed in 5 (11%) cases,
and was fatal in 1. A regimen of ATG 7.5mg/kg total ending on day21 effectively decreased the occurrence of
grade III-IV aGVHD and severe chronic GVHD.
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Acute and chronic graft-versus-host disease
(aGVHD, cGVHD) remain significant sources of
morbidity and mortality following allogeneic donor
hematopoietic cell transplantation (HCT). As donor
alloreactive T cells are principal mediators of the syn-1Blood and Marrow Transplantation, Moffitt Cancer
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6/j.bbmt.2010.12.705drome, in vivo T cell depletion by antilymphocyte
antibodies have been studied in the prevention
[1,2], pre-emptive therapy [3,4], and treatment of
established GVHD following HCT [5-10].
The efficacy of anti-thymocyte globulin (ATG)
in the prevention of both aGVHD and cGVHD
is supported by evidence including retrospective
comparative data [11-15] as well as randomized and
nonrandomized prospective clinical trials [16-28].
Studies have demonstrated reduction in aGVHD, and
long-term follow up has demonstrated significantly
lower cGVHD, lung dysfunction, and late nonrelapse
mortality (NRM) in those treated with ATG [29,30].
Alongside the beneficial reduction in GVHD, the use
of ATG delays immune reconstitution [31-34] and
confers an increased risk of Ebstein-Barr virus (EBV)
reactivation and EBV-associated posttransplant lym-
phoproliferative disease (PTLD) [35,36]. Risk of
PTLD increases with age, T cell depletion, ATG1237
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Posttransplantation monitoring of EBV viral load and
preemptive rituximab therapy is effective in controlling
EBV and preventing PTLD in the majority of cases
[37-40].
Diverse approaches to the delivery of antilympho-
cyte antibodies have been pursued to date, including
the following: rabbit ATG (Thymoglobulin) 4.5 mg/
kg total, divided over 3 days concluding on day
0 [12]; Thymoglobulin 7.5 mg/kg total, divided on
days 24 and 23, or Thymoglobulin 15 mg/kg total,
divided from days 25 to22 [16]; and ATG-Fresenius
(ATG-F; Fresenius Biotech, Graefelfing, Germany)
total dose ranging from 30 to 90 mg/kg, ending on
day 21 [11,19,41]. Comparative data suggest that
ATG potency varies among formulations, increases
with dose and with shorter time interval to HCT
[16,41-43]. Here, we report the safety and efficacy of
Thymoglobulin 7.5 mg/kg total, administered over 3
days ending on day 21, for the prevention of
aGVHD in mismatched unrelated donor HCT.METHODS
Patient Characteristics
Adult patients who received ATG for GVHD
prophylaxis before HLAmismatched, unrelated donor
HCT were the subjects of a retrospective study
approved by the University of South Florida institu-
tional review board. Consecutive patients between
September 2006 and March 2010 were identified by
review of existing database records. Inclusion criteria
were the use of ATG as GVHD prevention, and
a transplant from an HLA mismatched unrelated
donor. Recipient-donor pairs with sole mismatch at
HLA-DQ, or complete allelic matching at loci A, B,
C, and DR were excluded. Additionally, recipients of
umbilical cord blood stem cells were excluded from
this analysis. The principal aim of the study was to
estimate the cumulative incidence of grade III-IV
aGVHD.
Baseline characteristics included the following:
date of HCT; stem cell product infusion time; recipi-
ent and donor HLA typing; recipient and donor age,
gender, and cytomegalovirus (CMV) serostatus; dis-
ease condition and remission status at time of HCT;
conditioning regimen; aGVHD prophylaxis agents;
and ATG utilization (start date and time, schedule of
delivery, total dose delivered, stop date, and time).
Standardized data abstraction was performed.
Neutrophil engraftment was defined by the first of 3
successive days with an absolute neutrophil count of
.500/mL. Platelet engraftment was defined by the first
of 3 successive days with a nontransfused platelet count
of .20,000/mL. Primary graft failure was defined as
failure to achieve a neutrophil count of $500/mL inpatients who survived$28 days following transplanta-
tion and who have not undergone a second transplant
procedure. Secondary graft failure was defined as a de-
cline of neutrophils to\500/mL after having engrafted
that is unresponsive to growth factors. Acute GVHD
was scored per modified Glucksberg criteria [44].
Chronic GVHD was scored per the proposed NIH
consensus criteria [45]. Chimerism was assessed by
capillary electrophoresis of single tandem repeats on
peripheral blood sorted CD3- and CD33-positive cells
and bone marrow cells at days 30, 90, 180, and 360.
Absolute lymphocyte counts, and lymphocyte subsets
were quantified at 3, 6, and 12 months following
HCT. Data collected included CMV reactivation on-
set date and serum copy number, peak date and copy
number, number of discrete episodes of reactivation,
the occurrence and site of CMV disease, and CMV
therapy delivered. Data also included the date and
log copy number of EBV reactivation, peak date, and
copy number, number of doses of rituximab delivered,
and the occurrence of PTLD. Data were also gathered
on the occurrence of adenovirus, HHV-6, and BK vi-
rus following HCT. The occurrence of bacterial and
invasive fungal infections was also captured.Conditioning Therapy and ATG Regimen
The conditioning regimen in 41 of the 45 cases
consisted of fludarabine, 40 mg/m2 infused over 30
minutes on days 26 to 23, followed by intravenous
busulfan, 130 to 145 mg/m2 over 4 hours daily on
the same days. Busulfan PK-samples were obtained
on day 26 and analyzed by mass spectrometry; on
days24 and-3. The busulfan dose was adjusted to tar-
get an average area under the curve (AUC) of 5300
(610%) mMol*min (n 5 36) or 3500 (610%) mMol*-
min (n5 3) for each of the 4 days; the reduced busulfan
target AUC was selected according to transplant phy-
sician discretion in these 3 cases because of patient age
at transplant (range: 62-67 years of age). Two patients
were enrolled on a prospective trial examining dose es-
calation of i.v. pharmacokinetic- targeted busulfan and
fludarabine with a target average AUC of 7500 mMol*-
min. Three patients (multiple myeloma, n 5 2, acute
myelogenous leukemia, n 5 1) received fludarabine
40 mg/m2 on days 25 through 22 with melphalan
70 mg/m2 on day 22. Finally, 1 patient with aplastic
anemia was conditioned with fludarabine 30 mg/m2
and cyclophosphamide 300 mg/m2 on days 25
through 22, and 200 cGy total-body irradiation
(TBI) on day 0.
The ATG regimen provided a total of 7.5 mg/kg
rabbit ATG, administered as 1 mg/kg on day 23
(over $6 hours), then 3.25 mg/kg/day on days 22
and21 (over$4 hours) prior to the stem cell infusion.
The dose of ATG was based on actual body weight;
however, if actual body weight was $30% ideal body
Table 1. Baseline Characteristics of ATG-Treated HCT
Recipients
Age in years Median 48 (range: 22-67)
Year HCT performed
2007 12
2008 9
2009 19
2010 5
Recipient:donor gender match
F:F 10
F:M 10
M:M 18
M:F 7
Disease
AA 1
ALL
CR1 2
CR2 2
CR3 1
AML
CR1 11
CR2 11
CR3 2
CLL (relapsed) 1
CML
CP 1
AP 1
CMML/MPD 2
HD
CR2 2
REL1 1
MDS 4
MM
PR 1
VGPR 1
NHL (CR3) 1
Conditioning regimen
Bu/Flu
AUC 3500 3
AUC 5300 36
AUC 7500 2
FluMel 3
Flu/Cy/TBI 1
Recipient:donor CMV serostatus
Neg:neg 7
Neg:pos 5
Pos:neg 18
Pos:pos 15
GVHD prophylaxis
TAC/MTX 40
TAC/MMF 2
TAC/RAPA 3
Recipient:donor HLA disparity
A
Antigen 11
Allele 3
A+DRB 1
B
Antigen 10
Allele 4
C
Antigen 4
Allele 4
B+C 1
DRB
Antigen 7
AA indicates aplastic anemia; ALL, acute lymphoblastic leukemia; AML,
acute myelogenous leukemia; CML, chronic myelogenous leukemia;
CLL, chronic lymphocytic leukemia; CMML/MPD, chronic myelomono-
cytic leukemia, myeloproliferative disorder; HD, Hodgkin lymphoma;
MDS, myelodysplastic syndrome; MM, mulitple myeloma; NHL, non-
Hodgkin lymphoma; Bu/Flu, pharmacokinetic-targeted i.v. busulfan and
fludarabine; FluMel, fludarabine and melphalan; Flu/cy/TBI, fludarabine,
cyclophosphamide, total-body irradiation; CMV, cytomegalovirus;
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weight (adjusted body weight 5 [ideal body weight 1
actual body weight]/2). Standard supportive care in-
cluded the following: on day 23, methylprednisolone
2 mg/kg was given i.v. 1 hour prior to ATG infusion.
As well, starting 6 hours after the 2 mg/kg loading
dose on day 23 through day 21, methylprednisolone
1 mg/kg was given i.v. every 12 hours  5 total doses.
Additional supportive care included acetaminophen,
diphenhydramine, and dilaudid. Standardized proto-
col existed for management of anaphylactic reactions.
Statistical Methods
Baseline characteristics were summarized using
descriptive statistics. Accounting for competing risk
events, cumulative incidence of primary disease relapse
and nonrelapse mortality (NRM) was calculated [46].
Similarly, the cumulative incidence of acute (grade
II-IV, and separately, grade III-IV) and cGVHD
(any grade cGVHD, and separately, moderate to se-
vere cGVHD) was estimated. Overall survival (OS)
was estimated from date of transplantation using the
Kaplan-Meier method. The cumulative incidence for
each of CMV (according to recipient-donor serosta-
tus), EBV, adenovirus, HHV-6, BK, bacterial, and
invasive fungal infections was calculated. All analyses
were performed using NCSS 2007 software version
7.1.20 (NCSS.LLC Kaysville, Utah).RESULTS
Patient Characteristics
A consecutive series of 45 unrelated donor HCT
recipients matched at 6/8 or 7/8 HLA-A, -B, -C, or -
DRB1 loci received ATG (Thymoglobulin, Genzyme,
Cambridge, MA) for GVHD prevention from
September 2006 to March 2010 at Moffitt Cancer
Center. Analysis and reporting of this data was ap-
proved by the University of South Florida institutional
review board. Baseline characteristics are described in
Table 1.HCT consisted uniformly of peripheral blood
mobilized stem cells. ATG delivery was intended to be
completed on day 21. In this series, the actual time
elapsed between completion of ATG infusion and start
time of stem cell infusion was a median of 18 hours
(range: 5-39 hours).
Engraftment and Donor Chimerism
Delivery of ATG was well tolerated with no cases
of anaphylaxis. ATG did not interfere with the delivery
of conditioning chemotherapy or aGVHD prophy-
laxis agents. There were no cases of primaryTAC, tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil;
RAPA, sirolimus; HCT, hematopoietic stem cell transplantation; ATG,
anti-thymocyte globulin.
1240 Biol Blood Marrow Transplant 17:1237-1244, 2011J. Pidala et al.engraftment failure. Neutrophil (median 15 days,
range: 11-25) and platelet (median 16 days, range: 7-
31) engraftment was not delayed. Following predomi-
nantly myeloablative conditioning, sustained full do-
nor chimerism was promptly established following
HCT in the majority of cases. On day 30 after
HCT, median donor chimerism for CD3 was 100%
(range: 21%-100%), CD33 was 100% uniformly,
and unsorted bone marrow chimerism was 100%
(range: 90%-100%). By day 90 after HCT,median do-
nor chimerism for CD3 was 100% (range: 0%-100%),
CD33 was 100% (range: 97%-100%), and bone mar-
row was 97% (86%-100%). At 1 year, donor chime-
rism for CD3 was 97% (0%-100%), CD33 was
100% (44%-100%), and bone marrow was 97%
(84%-100%). In 1 case, donor chimerism was lost in
the CD3 compartment by 90 days post-HCT; the pa-
tient survives and remains free of relapse 35 months
post-HCT. One other patient failed to achieve full do-
nor chimerism in the CD3 compartment, with 21%
donor CD3 by day 30 post-HCT; serial measures
have demonstrated progressive loss of donor chime-
rism in both CD3 and CD33 compartments. The pa-
tient remains alive, and free of relapse with 6 months
of follow-up thus far.GVHD
The cumulative incidence of grade II-IV acute
GVHD was 64% (95% confidence interval [CI]
52%-80%). There was an overall incidence of severe,
grade III-IV aGVHD (Figure 1) of 11% by 100 days
(95% CI 5%-25%). Accounting for late aGVHD
(without concurrent manifestations of cGVHD), the
cumulative incidence of grade III-IV aGVHD by 1
year was 18% (95% CI 10%-34%). Skin was involved
in 44% of cases, gastrointestinal (GI) in 78%, and liver
in 11%. Of those with skin involvement, severity dis-
tribution was the following: grade 1 in 65%, 2 in0.000
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Figure 1. Cumulative incidence of grade III-IV aGVHD from date of
HCT.25%, and 3 in 10%. Of those with GI involvement,
severity distribution was: grade 1 in 74%, 2 in 9%, 3
in 14%, and grade 4 in 3%. Finally, of those with liver
involvement, distribution was as follows: grade 1 in
20%, 2 in 20%, 3 in 20%, and 4 in 40%.
Initial therapy for aGVHD consisted of systemic
glucocorticoids in all cases, with median starting
dose of 1 mg/kg/day (range: 0.16-2 mg/kg/day).
Secondary therapy was utilized for ongoing GVHD
manifestations (n 5 15) or steroid dependence
(n 5 9) according to transplant physician discretion
in 24 total patients. Agents utilized were the following:
mycophenolate mofetil in 12 cases, rapamycin in 16,
infliximab in 3, extracorporeal photopheresis (ECP)
in 2, and pentostatin in 1 case.
Of those at risk, the overall cumulative incidence of
any grade cGVHD was 35% (95% CI 23%-53%) at 1
year, and 43% (95% CI 29%-63%) by 2 years. The
cumulative incidence of moderate to severe cGVHD
(Figure 2) was 19% (95% CI 10%-36%) at 1 year,
and 28% (95% CI 16%-48%) at 2 years.Survival, Relapse, and NRM
With a median follow-up time for surviving pa-
tients of 12 months (range: 5-39 months), OS was
55% (95% CI 39%-71%) at 1 year, and 45% (95%
CI 27%-63%) at 2 years (Figure 3). A total of 9 patients
died following primary disease relapse posttransplan-
tation. Of these 9 relapse-related deaths, 6 died
directly from relapse, 1 died from parainfluenza pneu-
monia, 1 from refractory aGVHD after manipulation
of immune suppression in relapse, and 1 died as a result
of EBV reactivation with biopsy-confirmed PTLD
leading to multiorgan system failure. A total of 12
patients died in the absence of disease relapse. Of these
nonrelapse deaths, causes of death were pneumonia
and respiratory failure (n 5 2), septic shock and
multiorgan failure (n 5 1), aGVHD (n 5 4), cGVHDFigure 2. Cumulative incidence of moderate to severe cGVHD (per
NIH severity criteria) from date of HCT.
Figure 3. Kaplan-Meier plot of OS from date of HCT. Numbers with
available data: 3 months lymph (n5 24), CD4 (n5 11); 6 months lymph
(n 5 23), CD4 (n 5 12); 12 months lymph (n 5 13), CD4 (n 5 8).
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CMV pneumonia and respiratory failure (n 5 1), and
not known (n 5 1). The cumulative incidence of
NRM was 11% (95% CI 5%-25%) by 100 days
post-HCT, 26% (95% CI 16%-44%) by 1 year, and
30% (95% CI 18%-50%) by 2 years. The cumulative
incidence of primary disease relapse was 23% (95%
CI 13%-41%) by 1 year, and 33% (95% CI 20%-
56%) by 2 years post-HCT. These data on primary
disease relapse post-HCT should be interpreted with
caution given the heterogeneity in disease conditions
and remission status represented in this series.
Immune Reconstitution and Infectious
Complications
Data on absolute lymphocyte and immune cell sub-
sets were abstracted at 3, 6, and 12 months post-HCT.
From those with available data, absolute lymphocyteFigure 4. Absolute lymphocyte and CD4 lymphocyte reconstitution at
3, 6, and 12 months following date of HCT.and CD4 counts are presented in Figure 4. These
data demonstrate impaired immune reconstitution.
Notably, the median CD4 count remained below
200/mL by 12 months following HCT.
CMV viral load by PCR was monitored at least
weekly, and preemptive therapy was initiated when
copy number surpassed 1000/mL. The overall cumu-
lative incidence of CMV reactivation was 60% (95%
CI 47%-76%), which differed according to recipient/
donor CMV serostatus prior to HCT-negative/
positive 40% (95% CI 14%-100%); positive/negative
83% (95% CI 68%-100%); and positive/positive
53% (95% CI 33%-86%). Peak copy number was
a mean of 22,783 copies/mL, and the median number
of discrete episodes (new episodes characterized by
resolution of the prior episode, then reactivation of
CMV) was 1 (range: 1-4). Confirmed CMV organ
involvement was present in 7 total cases (pulmonary
3, gastrointestinal 2, central nervous system 1, and
urinary bladder 1). The median time from first detec-
tion of CMV to diagnosis of CMV disease in these 7
cases was 106 days (range: 10-284 days). The copy
number at first detection of CMV in these 7 cases
was a median of 700 copies/mL (range: 500-1350
copies/mL), and progressed to a median peak value
of 3000 copies/mL (range: 1350-9950 copies/mL).
Therapy with valganciclovir or foscarnet was initiated
when copy number exceeded 1000 copies/mL. This
therapy successfully managed CMV reactivation and
disease in all but 1 patient who died with CMV
pneumonia and respiratory failure.
EBVwasmonitoredweekly followingHCT for pa-
tients who received transplants from 8/1/07 onward
(n 5 40 total); there were 5 cases prior to this point
wherein EBV was not systematically monitored on
a weekly basis post-HCT. Of these 5 cases, 1 patient
was found to have EBV reactivation approximately 5
months after HCT, but died within a month of this
fromGVHD and pneumonia. No clinical or patholog-
ical evidence of PTLD was present in these 5 cases.
Considering only the 40 remaining patients in which
EBV was systematically monitored weekly following
HCT, the cumulative incidence of EBV reactivation
was 54% (95% CI 40%-71%). The median peak value
for EBV copy number was 4.1 log (range: 2.9-6.7).
Preemptive therapy with rituximab at 375 mg/m2
weekly was administered when EBV copy number
exceeded 1000 per mL. Of 23 patients with EBV
reactivation, a total of 21 patients received rituximab
at amedian of 4 doses (range: 1-6). The remaining 2 pa-
tients were not treated with rituximab. One had a max-
imum value of 750 copies/mL and resolved without
treatment. The other patient had a peak EBV viremia
of 1000 copies/mL, but was not treated in the setting
of critical illness with refractory GVHD and pneumo-
nia. PTLD was diagnosed at a median of 3 months
(range: 1-9 months) post-HCT in 5 total cases; 2 of
1242 Biol Blood Marrow Transplant 17:1237-1244, 2011J. Pidala et al.these were biopsy confirmed, whereas the others were
diagnosed based on radiographic and clinical findings.
Of these 5 cases, 1 died with multiorgan system failure
in the setting of uncontrolled EBV-associated PTLD.
Two others died of sepsis, 1 from GVHD, and 1 from
relapsed primary disease.
Other infectious complications examined included
the following: adenoviral infection was detected in 4%
(95% CI 1%-17%). Human Herpes Virus 6 (HHV6)
reactivation was detected in 9% (95% CI 3%-23%).
Of these, none had end-organ involvement including
pneumonitis or encephalitis. Significant BK virus
infection defined by plasma BK virus copy number
occurred in 42% (95% CI 30%-60%). Median BK
log copy number was 3.9 (range: 2.9-8.6). These cases
were successfully treated with either leflunomide or
cidofovir. Invasive fungal infections occurred in 28%
(95% CI 17%-48%). Fungal species isolated included
Candida (n 5 7), Cryptococcus (n 5 1), Aspergillus
(n5 3), andMucor species (n5 1). Three total patients
died from disseminated fungal infection. Finally, 57%
(95% CI 44%-75%) experienced bacterial infection
followingHCT.Organisms identifiedwere aheteroge-
neous array ofGram- positive and -negative organisms.
Of those affected, 3 died from bacterial sepsis.DISCUSSION
Severe aGVHD remains a significant obstacle to
successful unrelated donor HCT. The risk of severe
aGVHD and the associated NRM is even greater in
the setting of HLA mismatch. To mitigate this risk,
we have employed a regimen of rabbit ATG 7.5 mg/
kg for the prevention of severe aGVHD after HCT
from unrelated donors matched for 6/8 or 7/8 HLA
alleles at -A, -B, -C, or -DRB1. We have utilized
Thymoglobulin, as allied evidence from solid organ
allografting demonstrates that ATG is more immuno-
suppressive than Atgam (anti-thymocyte globulin
[equine];) [47-49]. As well, ATG is associated with
no delay in engraftment, in contrast to ATG-
Fresenius, which prolongs neutropenia and thrombo-
cytopenia [19]. On the basis of data from the 2 small
randomized controlled trials from Bacigalupo et al.
[16], we selected the ATG regimen of 7.5 as opposed
to the 15 mg/kg total dose to minimize toxicity from
opportunistic infections, but decided to delay the
schedule of administration to days 23, 22, and 21
before HSCT to optimize efficacy.
The combination of tacrolimus and methotrexate
plus ATG7.5mg/kg delivered on days23 to21 effec-
tively prevented severe (grades III-IV) aGVHD in this
series of high-risk patients in all but 11%. In
comparison, a largeNationalMarrowDonor Program
(NMDP) analysis demonstrated grade III-IV aGVHD
in 37% of those with 7/8, and 40% in those with 6/8recipient-donor mismatch; importantly, only 24% of
the 7/8 mismatched unrelated donor HCT recipients
in the NMDP analysis had either ex vivo or in vivo
T cell depletion by ATG or other antibodies [50].
The cumulative incidence of grade III-IV aGVHDap-
proximates that reported in randomized trials of ATG
prevention in completely matched unrelated donor
HCT [12,16]. The efficacy of this approach is likely
related to the dose and the proximity of ATG
delivery to the infusion of the allograft, in keeping
with prior literature, which suggests an association
between prevention of severe aGVHD and timing of
ATG pre-HCT. Direct comparisons to prior series
and randomized trials are limited, however, by the dis-
parate pharmacological prophylaxis agents (entirely
tacrolimus combination regimens in this series versus
cyclosporine/methotrexate in prior trials) utilized in
concert with ATG, as well as the divergent stem cell
products (uniformly peripheral blood mobilized stem
cells in our series). The incidence of any grade cGVHD
in this series approximates that reported in other stud-
ies, but we have notably observed an overall low inci-
dence of moderate to severe cGVHD. We
acknowledge the relatively limited follow-up time in
this series, and the likelihood that more mature data
will provide a better estimate of the true incidence of
moderate to severe cGVHD in this patient series. Fur-
ther comparisons to existing literature are limited by
the use of limited/extensive scoring in prior studies
and our use of the recommendedNIHconsensus sever-
ity scoring in this series. Finally, the overall outcomes
in this series compare favorably with existing literature.
One year OS was 55% in this series, compared to 43%
and 33% for 7/8 and 6/8 mismatched unrelated donor
transplants in the NMDP analysis, respectively. We
have also explored difference in outcomes between
those with antigen-versus allele-level mismatch in our
series: although moderate to severe cGVHD was sig-
nificantly lower in those with allele-level mismatch
(P 5 .04), all other major outcomes (grade II-IV
aGVHD, III-IV aGVHD, relapse, NRM, OS) did
not significantly differ. These conclusions are limited
by small sample size.
The regimen demonstrates an overall favorable
safety profile. In contrast to published estimates of
primary engraftment failure ranging from 13% to
17% for 6/8 and 7/8 HLA locus matched unrelated
donor transplants [50], we observed no cases of
primary engraftment failure. As well, donor chimerism
was promptly achieved and maintained in the majority
of these cases following primarily myeloablative condi-
tioning. NRM at 1 year (26% in our series) is lower
than the 45% to 55% previously reported for 6/8 or
7/8 HLA locus matched unrelated transplants [50].
Impaired immune reconstitution and infectious
complications represent established risks with the use
of antilymphocyte antibodies for in vivo T cell
Biol Blood Marrow Transplant 17:1237-1244, 2011 1243ATG Prevents Severe acute GVHDdepletion. With a strategy of vigilant monitoring and
preemptive therapy, CMV reactivation was largely
controlled in this series. However, several cases of
CMV disease were observed, including 1 death from
CMV pulmonary disease. Despite rituximab, PTLD
remains a potentially life-threatening complication.
Although there is robust evidence in support of
surveillance and preemptive therapy for EBV reactiva-
tion, primary prevention with prophylactic rituximab
post-HCT may attenuate this risk further. Early
evidence from a pilot trial conducted by Small et al.
[51] suggests marked suppression of EBV reactivation
and PTLDwith 6monthly prophylactic doses of ritux-
imab following T cell–depleted HCT. In total, the
beneficial reduction in severe aGVHD is balanced by
an increased risk of infectious complications, as well
as requirement for intensive monitoring and preemp-
tive therapy for CMV and EBV reactivation.
Acknowledging the limitations inherent in single-
center retrospective analyses, our data suggest marked
activity of ATG 7.5 mg/kg ending on day 21 in the
prevention of severe aGVHD in 6/8 or 7/8 matched
unrelated donor transplants. Antilymphocyte anti-
bodies appear to decrease the risk of severe aGVHD
in unrelated donor HCT. It is also important to
acknowledge the evidence to date, which substantiates
alternative T cell–depletion strategies, such as ex vivo
T cell depletion or alemtuzumab. The evidence avail-
able to date in the efficacy of antilymphocyte anti-
bodies for the prevention of severe aGVHD is
limited, however, and there is marked heterogeneity
in the utilization of these agents before HLA matched
or partially matched unrelated donorHCT. Data from
the Center for International Blood and Marrow
Transplant Research (CIBMTR) showed that, among
patients treated for acute myelogenous leukemia
(AML), acute lymphoblastic leukemia (ALL), chronic
myeloid leukemia (CML), and myelodysplastic syn-
drome (MDS) during 2009, only 395 of 1059 (37%) re-
ceived ATG for GVHD prophylaxis after HLA
matched or partially matched unrelated donor marrow
or peripheral blood HCT. Given these limitations, we
argue that a definitive randomized trial is needed to
discern the true benefit of ATG for the prevention of
severe aGHVD in unrelated donor transplantation.ACKNOWLEDGMENTS
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